Myeloablation followed by hematopoietic stem cell transplantation leads to long-term normalization of systemic sclerosis molecular signatures.
Nancy WareingXuan WangLynette Keyes-ElsteinEllen A GoldmuntzMarka A LyonsPeter McSweeneyDaniel E FurstRichard A NashLeslie J CroffordBeverly WelchAshley PinckneyMaureen D MayesKeith M SullivanShervin AssassiPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
Paralleling the observed clinical benefit, HSCT leads to durable long-term normalization of the molecular signature in SSc with completion of immune resetting to 54 months post-HSCT.